Foghorn Story

FHTX -- USA Stock

USD 10.61 0.16 1.49%

Macroaxis Story

The stock experiences an active upward rally. While many fundamental traders are getting carried away by overanalyzing balance sheets and income statements, it is reasonable to break down Foghorn Therapeutics against its basic efficiency ratios. We will analyze why it could be a much better year for Foghorn Therapeutics shareholders. Foghorn Therapeutics current probability of distress is under 33 percent. Will investors continue to be optimistic, or should we expect a sell-off?

Published over three weeks ago

View all stories for Foghorn Therapeutics | View All Stories

Are Foghorn Therapeutics (NASDAQ:FHTX) weak basic indicators contributing to the current slide?

The firm shows a Beta (market volatility) of -0.2421, which means not very significant fluctuations relative to the market. Let's try to break down what Foghorn's beta means in this case. As returns on the market increase, returns on owning Foghorn Therapeutics are expected to decrease at a much lower rate. During the bear market, Foghorn Therapeutics is likely to outperform the market. Even though it is essential to pay attention to Foghorn Therapeutics historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards predicting any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Foghorn Therapeutics exposes twenty-eight different technical indicators, which can help you to evaluate its performance. Foghorn Therapeutics has an expected return of -0.43%. Please be advised to confirm Foghorn Therapeutics total risk alpha, as well as the relationship between the downside variance and daily balance of power to decide if Foghorn Therapeutics stock performance from the past will be repeated at some point in the near future.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Foghorn Therapeutics income statement, its balance sheet, and the statement of cash flows. Potential Foghorn Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Foghorn Therapeutics investors may use each financial statement separately, they are all related. The changes in Foghorn Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Foghorn Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Foghorn Therapeutics fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Foghorn Therapeutics performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Foghorn Therapeutics shares is the value that is considered the true value of the share. If the intrinsic value of Foghorn is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Foghorn Therapeutics.

Please read more on our fundamental analysis page.

What is Foghorn Asset Breakdown?

Foghorn Therapeutics reports assets on its Balance Sheet. It represents the amount of Foghorn resources that either has an existing economic value or will provide some form of benefits in the future. To get a better handle on how balance sheet or income statements item affect Foghorn volatility, please check the breakdown of all its fundamentals

Are Foghorn Therapeutics Earnings Expected to grow?

The future earnings power of Foghorn Therapeutics involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Foghorn Therapeutics factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Foghorn Therapeutics stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Foghorn expected earnings.

Foghorn Therapeutics Gross Profit

Foghorn Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Foghorn Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Foghorn Therapeutics Gross Profit growth over the last 10 years.

Please check Gross Profit in more details.

Acquisition by Decicco Carl of 100000 shares of Foghorn Therapeutics subject to Rule 16b-3

Legal trades by Foghorn Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Foghorn insider trading alert for grant of stock option (right to buy) by Decicco Carl, Chief Scientific Officer, on 1st of February 2021. This event was filed by Foghorn Therapeutics Inc with SEC on 2021-02-01. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Perspective On Foghorn Therapeutics

Net Loss for the year was (58.06 M).

Asset Utilization

The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Foghorn suggests not a very effective usage of assets in March.

Current Assets

205.7 M

Assets Non Current

70 M

	Current Assets	205.74 Million	74.61
	Assets Non Current	70.03 Million	25.39

Our perspective of the current Foghorn Therapeutics rise

Current potential upside is at 6.65.

As of the 20th of March, Foghorn Therapeutics shows the mean deviation of 3.64, and Coefficient Of Variation of (1,203). Foghorn Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Foghorn Therapeutics, which can be compared to its rivals. Please confirm Foghorn Therapeutics mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to decide if Foghorn Therapeutics is priced favorably, providing market reflects its regular price of 16.12 per share. Given that Foghorn Therapeutics has jensen alpha of (0.51), we urge you to verify Foghorn Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Our Final Perspective on Foghorn Therapeutics

While many other companies under the biotechnology industry are still a bit expensive, Foghorn Therapeutics may offer a potential longer-term growth to investors. To conclude, as of the 20th of March 2021, we believe that at this point, Foghorn Therapeutics is somewhat reliable with below average chance of financial distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our latest 30 days buy-hold-sell recommendation on the company is Sell.

About Contributor

Raphi Shpitalnik is a Junior Member of Macroaxs Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time base at the beginning of the pandemic and eventually acquired a real test for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Foghorn Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC